Today on DrugResearcher.com   NIH cash for new tools to unravel genome's secrets Oxford Genome Sciences advances on Amgen deal Affymetrix simplifies genetic copy number analysis French CROs have eye on niche market Drugs moving into the clinic: 39

Related Industry News   Siegfried and Arena sign contract manufacturing deal Harvard Bioscience knocks back Skystone takeover bid ClinTec to take on India Patheon reveals plans to tackle Puerto Rico problems

Breaking News on Drug Discovery
Daily  Tuesday 18 December 2007		Forward to a colleague

	Access Full Stories NIH cash for new tools to unravel genome's secrets The technology used to decipher an organism's gene sequence has come on in leaps and bounds this year. So much so that the US National Institutes of Health (NIH) has now released funds to create new tools to analyse... Read Oxford Genome Sciences advances on Amgen deal Oxford Genome Sciences (OGeS) has taken a step closer to shedding its service provider skin and morphing into a pharma firm after entering a new cancer collaboration with Amgen, one of the world's largest biotech... Read Affymetrix simplifies genetic copy number analysis Affymetrix has launched a new analysis tool for determining genetic variations in whole-genome association and cytogenetic studies that is up to 10 times more sensitive than competing software... Read French CROs have eye on niche market Two French contract research organisations (CROs) that specialise in ophthalmology have banded together to offer specialised services to this niche market... Read Drugs moving into the clinic: 39 The last in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators... Read
	All News Headlines for: December | November | October
	Related Industry News Siegfried and Arena sign contract manufacturing deal Siegfried has signed a $27.7m contract with Arena Pharmaceuticals to manufacture Arena's Phase III oral obesity drug candidate lorcaserin hydrochloride... Read Harvard Bioscience knocks back Skystone takeover bid Harvard Bioscience has rejected an unsolicited acquisition offer from Skystone Advisors to acquire all outstanding shares of common stock in the life science tools and instrument manufacturer... Read ClinTec to take on India UK contract research organisation (CRO) ClinTec has outlined new expansion plans into India to try its luck in this country's burgeoning clinical contract research arena... Read Patheon reveals plans to tackle Puerto Rico problems Patheon has finally revealed its plans to tackle the ongoing problems it has been facing with its Puerto Rican operations, which are draining the firm of profitability... Read Weekly Comment Paediatric drugs and testing highlighted The importance of paediatric drug formulations and clinical trials in children was highlighted at this month's American Association of Pharmaceutical Scientists (AAPS) conference in San Diego. Read Previous Headlines Semen fibrils ferry HIV into cells Tiny protein fibres in semen have been found to enhance the ability of HIV to infect cells by up to 100,000 fold and could provide drug developers with a potent new target to tackle the virus... Read Shire snaps up Alba's gastrointestinal drug for $325m US biopharma firm Alba Therapeutics has received a boost to its coffers after Shire agreed to pay up to $325m (€226m) to help bring its lead gastrointestinal drug candidate to market... Read Japan says Tamiflu/psychiatric link unclear Any link between the antiviral Tamiflu and neuropsychiatric problems is inconclusive, according to the Japanese Government... Read Curiox' mini-bioassay tech to aid cheaper drug development Curiox Biosystems has developed a miniaturisation platform that enables cheaper and more efficient bioassays to be conducted, potentially slashing the costs of life science and drug discovery research... Read Biogen Idec shares nosedive after withdrawing 'for sale' sign Like countless pets after every Christmas, it seems that nobody wanted Biogen Idec after all; the firm has announced it will remain independent after it 'did not receive any definitive offers to purchase the company'... Read Technical / White Papers, Case studies, Web casts Benefits of integrating human tissue research in drug discovery - Technical / White Paper Manufacturing Variations in Polysorbate Batches - Technical / White Paper Product Information - brochures, Web centers Separation of polar compounds - Application Notes Product Innovation Alerts - Free of Charge Indicate your research interests and receive alerts on relevant products and market innovations Analysis and instrumentation Assays and screening Cell culture & Equipment Chromatography Compounds and consumables Contract services (outsourcing) Drug discovery Genomics / Proteomics Informatics & IT Lab equipment & consumables Liquid handling and automation Liquid handling and sample preparation Production technologies Separation and purification

	Free Newsletters for Pharmaceuticals Access now !Choose from over 20 industry e-newsletters Access Decision News Media e-newsletters for the food, beverage & nutrition industries, click here
	Forward to a colleague

	To continue to receive this newsletter in your inbox, please add newsletter@DrugResearcher.com to your address book
	Update preferences | Change your email address | Unsubscribe
	Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback
	© 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com